A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)

Celgene

Status and phase

Terminated

Phase 1

Conditions

Leukemia, Myeloid, Acute

Myelodysplastic Syndromes

Treatments

Drug: CC-90002

Study type

Interventional

Funder types

Industry

Identifiers

NCT02641002

CC-90002-AML-001

Details and patient eligibility

About

Study CC-90002-AML-001 is an open-label, Phase 1 dose escalation (Part A) and expansion (Part B), clinical study of CC-90002, administered by intravenous (IV) infusion, in subjects with relapsed and/or primary refractory AML and high-risk MDS. The study will explore escalating doses of CC-90002 using a 3 + 3 dose escalation design in Part A, followed by dose expansion in Part B.

The primary objective is to determine the safety and tolerability of CC-90002 and also to define the non-tolerated dose (NTD), the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CC-90002.

Full description

In both Part A and Part B, treatments will be administered in two phases starting with an induction phase followed by a maintenance phase. During the induction phase, treatments will be administered in 42-day cycles in Cycles 1 through 4. Following completion of Cycle 4 in the induction phase, subjects with non-progressive disease will enter the maintenance phase. During the maintenance phase, treatments will be administered in 28 day cycles. Subjects may continue CC-90002 for up to a maximum of 2 years (eg, induction phase Cycles 1 through 4 and maintenance phase Cycles 5 through 24) or until clinically significant disease progression, the occurrence of intolerable toxicity, or physician/subject decision to discontinue CC-90002, whichever comes first.

Enrollment

28 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Men and women ≥ 18 years of age, at the time of signing the informed consent form (ICF).
Relapsed and/or primary refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) with subtype refractory anemia with excess blasts (RAEB)-2 defined as high or very high-risk that is recurrent or refractory, or the patient is intolerant to established therapy.
Subject consents to hospitalization for first (Cycle 1 Day 1) dose of CC-90002 and for 72 hours after.
Subject consents to serial bone marrow aspiration and biopsies as specified.
Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2.
Eligible study subjects must exhibit acceptable liver, renal, and coagulation function as assessed by laboratory tests.
Females and males must practice true abstinence or agree to contraceptive methods throughout the study, and for up to 8 weeks following the last dose of CC 90002.

Exclusion criteria

Active central nervous system (CNS) leukemia or known CNS leukemia.
Immediately life-threatening, severe complications of leukemia.
Impaired cardiac function or clinically significant cardiac diseases.
Glucose-6-phosphate dehydrogenase (G6PD) deficiency.
Prior autologous hematopoietic stem cell transplant ≤ 3 months.
Prior allogeneic hematopoietic stem cell transplant (HSCT) with either standard or reduced intensity conditioning ≤ 6 months.
Systemic immunosuppressive therapy post HSCT or with clinically significant graft-versus-host disease (GVHD).
Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives or 4 weeks whichever is shorter.
Major surgery ≤ 2 weeks and recovered from any clinically significant effects of recent surgery.
Pregnant or nursing females.
Known HIV infection.
Known chronic hepatitis B or C (HBV/HCV) infection.
Ongoing treatment with chronic, therapeutic dosing of anti-coagulants.
History of autoimmune hemolytic anemia or autoimmune thrombocytopenia.
History of concurrent second cancers requiring active, ongoing systemic treatment.
Subjects for whom potentially curative anticancer therapy is available.